Karuna Therapeutics Inc expected to post a loss of $2.65 a share - Earnings Preview

Karuna Therapeutics

19/02/2024 14:23

* Karuna Therapeutics Inc  KRTX.OQ   KRTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
21 (estimated) for the period ending December 31 2023
    * The Boston Massachusetts-based  company is expected to
report a
85.6% decrease in revenue to $761.18 thousand from $5.28 million
a year ago, according to the mean estimate from 17 analysts,
based on LSEG data. (Majority is on Total Revenue basis)
    * ​LSEG's mean analyst estimate for Karuna Therapeutics Inc
is for
a loss of $2.65 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 15
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Karuna
Therapeutics Inc is $330.00​, above​ its last closing price
of $318.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -2.75       -2.74      -3.16     Missed  -15.2
 Jun. 30 2023  -2.80       -2.78      -2.75     Beat    0.9
 Mar. 31 2023  -2.79       -2.76      -2.80     Missed  -1.6​
 Dec. 31 2022  -2.37       -2.25      -2.22     Beat    1.2
 ​​Sep.        -2.13       -2.13      -2.38     Missed  -11.5
 30 2022                                                
 Jun. 30 2022  -2.04       -2.09      -2.17     Missed  -3.6​
 Mar. 31 2022  -2.18       -2.11      -1.95     Beat    7.6
 Dec. 31 2021  -1.66       -1.73      -0.94     Beat    45.8
 This summary was machine generated February 19 at 14:22 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)